nodes	percent_of_prediction	percent_of_DWPC	metapath
Travoprost—PTGFR—Small Ligand GPCRs—CNR2—atherosclerosis	0.0227	0.0934	CbGpPWpGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—EDNRA—atherosclerosis	0.0123	0.0504	CbGpPWpGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—EDN1—atherosclerosis	0.00885	0.0363	CbGpPWpGaD
Travoprost—Peptic ulcer—Niacin—atherosclerosis	0.00823	0.0109	CcSEcCtD
Travoprost—Eye irritation—Lovastatin—atherosclerosis	0.0075	0.00994	CcSEcCtD
Travoprost—Tenderness—Lovastatin—atherosclerosis	0.00734	0.00973	CcSEcCtD
Travoprost—Accidental injury—Lovastatin—atherosclerosis	0.00724	0.0096	CcSEcCtD
Travoprost—Bone disorder—Ezetimibe—atherosclerosis	0.00695	0.00922	CcSEcCtD
Travoprost—Tenderness—Simvastatin—atherosclerosis	0.00687	0.0091	CcSEcCtD
Travoprost—Cataract—Lovastatin—atherosclerosis	0.00673	0.00892	CcSEcCtD
Travoprost—Musculoskeletal pain—Lovastatin—atherosclerosis	0.00648	0.00859	CcSEcCtD
Travoprost—Inflammation—Ezetimibe—atherosclerosis	0.00648	0.00859	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—HRH1—atherosclerosis	0.00636	0.0261	CbGpPWpGaD
Travoprost—Cataract—Simvastatin—atherosclerosis	0.00629	0.00834	CcSEcCtD
Travoprost—Tenderness—Pravastatin—atherosclerosis	0.00621	0.00823	CcSEcCtD
Travoprost—Inflammation—Simvastatin—atherosclerosis	0.00618	0.00819	CcSEcCtD
Travoprost—Skin discolouration—Niacin—atherosclerosis	0.00609	0.00807	CcSEcCtD
Travoprost—Bone disorder—Niacin—atherosclerosis	0.00609	0.00807	CcSEcCtD
Travoprost—Injury—Rosuvastatin—atherosclerosis	0.00597	0.00791	CcSEcCtD
Travoprost—Cataract—Pravastatin—atherosclerosis	0.00569	0.00754	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRH1—atherosclerosis	0.00568	0.0234	CbGpPWpGaD
Travoprost—Musculoskeletal pain—Pravastatin—atherosclerosis	0.00548	0.00727	CcSEcCtD
Travoprost—Dermatitis contact—Niacin—atherosclerosis	0.00544	0.00721	CcSEcCtD
Travoprost—Injury—Lovastatin—atherosclerosis	0.00506	0.00671	CcSEcCtD
Travoprost—PTGFR—GPCRs, Other—EDNRA—atherosclerosis	0.00505	0.0208	CbGpPWpGaD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—atherosclerosis	0.00493	0.0203	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—HRH1—atherosclerosis	0.00491	0.0202	CbGpPWpGaD
Travoprost—Abnormal vision—Niacin—atherosclerosis	0.0048	0.00636	CcSEcCtD
Travoprost—Arthritis—Lovastatin—atherosclerosis	0.00478	0.00634	CcSEcCtD
Travoprost—Influenza—Rosuvastatin—atherosclerosis	0.00474	0.00629	CcSEcCtD
Travoprost—Arthritis—Ezetimibe—atherosclerosis	0.00469	0.00622	CcSEcCtD
Travoprost—Bronchitis—Rosuvastatin—atherosclerosis	0.00456	0.00605	CcSEcCtD
Travoprost—Arthritis—Simvastatin—atherosclerosis	0.00447	0.00593	CcSEcCtD
Travoprost—Injury—Pravastatin—atherosclerosis	0.00428	0.00567	CcSEcCtD
Travoprost—Depression—Rosuvastatin—atherosclerosis	0.00422	0.00559	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—HRH1—atherosclerosis	0.00421	0.0173	CbGpPWpGaD
Travoprost—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00411	0.00545	CcSEcCtD
Travoprost—Arthritis—Niacin—atherosclerosis	0.00411	0.00545	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—UTS2—atherosclerosis	0.0041	0.0168	CbGpPWpGaD
Travoprost—Arthritis—Pravastatin—atherosclerosis	0.00405	0.00536	CcSEcCtD
Travoprost—Influenza—Lovastatin—atherosclerosis	0.00402	0.00533	CcSEcCtD
Travoprost—Sinusitis—Rosuvastatin—atherosclerosis	0.00397	0.00526	CcSEcCtD
Travoprost—Influenza—Ezetimibe—atherosclerosis	0.00394	0.00523	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—CASR—atherosclerosis	0.00393	0.0161	CbGpPWpGaD
Travoprost—Rhinitis—Rosuvastatin—atherosclerosis	0.0038	0.00504	CcSEcCtD
Travoprost—Pharyngitis—Rosuvastatin—atherosclerosis	0.00377	0.00499	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—UTS2—atherosclerosis	0.00366	0.015	CbGpPWpGaD
Travoprost—Bronchitis—Simvastatin—atherosclerosis	0.00361	0.00479	CcSEcCtD
Travoprost—Infestation NOS—Ezetimibe—atherosclerosis	0.00351	0.00466	CcSEcCtD
Travoprost—Infestation—Ezetimibe—atherosclerosis	0.00351	0.00466	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—CASR—atherosclerosis	0.00351	0.0144	CbGpPWpGaD
Travoprost—Urinary tract infection—Lovastatin—atherosclerosis	0.00348	0.00462	CcSEcCtD
Travoprost—Influenza—Niacin—atherosclerosis	0.00345	0.00458	CcSEcCtD
Travoprost—Influenza—Pravastatin—atherosclerosis	0.0034	0.00451	CcSEcCtD
Travoprost—Angina pectoris—Niacin—atherosclerosis	0.00336	0.00446	CcSEcCtD
Travoprost—Sinusitis—Lovastatin—atherosclerosis	0.00336	0.00446	CcSEcCtD
Travoprost—Depression—Simvastatin—atherosclerosis	0.00334	0.00443	CcSEcCtD
Travoprost—Mental disorder—Rosuvastatin—atherosclerosis	0.00332	0.00441	CcSEcCtD
Travoprost—Bronchitis—Niacin—atherosclerosis	0.00332	0.0044	CcSEcCtD
Travoprost—Angina pectoris—Pravastatin—atherosclerosis	0.00331	0.00439	CcSEcCtD
Travoprost—Sinusitis—Ezetimibe—atherosclerosis	0.0033	0.00437	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—HRH1—atherosclerosis	0.00321	0.0132	CbGpPWpGaD
Travoprost—Dysuria—Pravastatin—atherosclerosis	0.00318	0.00421	CcSEcCtD
Travoprost—Sinusitis—Simvastatin—atherosclerosis	0.00314	0.00417	CcSEcCtD
Travoprost—Pharyngitis—Ezetimibe—atherosclerosis	0.00313	0.00415	CcSEcCtD
Travoprost—Connective tissue disorder—Ezetimibe—atherosclerosis	0.0031	0.00411	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL4—atherosclerosis	0.00304	0.0125	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CX3CR1—atherosclerosis	0.00304	0.0125	CbGpPWpGaD
Travoprost—Depression—Pravastatin—atherosclerosis	0.00302	0.00401	CcSEcCtD
Travoprost—Urinary tract infection—Pravastatin—atherosclerosis	0.00294	0.0039	CcSEcCtD
Travoprost—Cough—Rosuvastatin—atherosclerosis	0.00288	0.00382	CcSEcCtD
Travoprost—Angiopathy—Ezetimibe—atherosclerosis	0.00286	0.00379	CcSEcCtD
Travoprost—Immune system disorder—Ezetimibe—atherosclerosis	0.00285	0.00378	CcSEcCtD
Travoprost—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00284	0.00377	CcSEcCtD
Travoprost—Sinusitis—Pravastatin—atherosclerosis	0.00284	0.00377	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—EDNRA—atherosclerosis	0.00284	0.0117	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CNR2—atherosclerosis	0.00282	0.0116	CbGpPWpGaD
Travoprost—Myalgia—Rosuvastatin—atherosclerosis	0.00281	0.00373	CcSEcCtD
Travoprost—Arthralgia—Rosuvastatin—atherosclerosis	0.00281	0.00373	CcSEcCtD
Travoprost—Rhinitis—Niacin—atherosclerosis	0.00277	0.00367	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—GHRL—atherosclerosis	0.00277	0.0114	CbGpPWpGaD
Travoprost—Mental disorder—Ezetimibe—atherosclerosis	0.00276	0.00366	CcSEcCtD
Travoprost—Erythema—Ezetimibe—atherosclerosis	0.00275	0.00364	CcSEcCtD
Travoprost—Dysgeusia—Lovastatin—atherosclerosis	0.00274	0.00364	CcSEcCtD
Travoprost—Rhinitis—Pravastatin—atherosclerosis	0.00273	0.00362	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—UTS2—atherosclerosis	0.00271	0.0111	CbGpPWpGaD
Travoprost—Back pain—Lovastatin—atherosclerosis	0.00271	0.00359	CcSEcCtD
Travoprost—Pharyngitis—Pravastatin—atherosclerosis	0.0027	0.00358	CcSEcCtD
Travoprost—Infection—Rosuvastatin—atherosclerosis	0.00268	0.00355	CcSEcCtD
Travoprost—Visual impairment—Niacin—atherosclerosis	0.00266	0.00353	CcSEcCtD
Travoprost—Back pain—Ezetimibe—atherosclerosis	0.00266	0.00352	CcSEcCtD
Travoprost—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00264	0.00351	CcSEcCtD
Travoprost—Vision blurred—Lovastatin—atherosclerosis	0.00264	0.0035	CcSEcCtD
Travoprost—Mental disorder—Simvastatin—atherosclerosis	0.00264	0.00349	CcSEcCtD
Travoprost—Visual impairment—Pravastatin—atherosclerosis	0.00262	0.00348	CcSEcCtD
Travoprost—Erythema—Simvastatin—atherosclerosis	0.00262	0.00347	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CX3CR1—atherosclerosis	0.0026	0.0107	CbGpPWpGaD
Travoprost—Ill-defined disorder—Lovastatin—atherosclerosis	0.0026	0.00344	CcSEcCtD
Travoprost—Eye disorder—Niacin—atherosclerosis	0.00258	0.00342	CcSEcCtD
Travoprost—Tinnitus—Niacin—atherosclerosis	0.00258	0.00341	CcSEcCtD
Travoprost—Dysgeusia—Simvastatin—atherosclerosis	0.00256	0.0034	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CX3CL1—atherosclerosis	0.00255	0.0105	CbGpPWpGaD
Travoprost—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00255	0.00338	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—atherosclerosis	0.00254	0.0104	CbGpPWpGaD
Travoprost—Tinnitus—Pravastatin—atherosclerosis	0.00254	0.00336	CcSEcCtD
Travoprost—Malaise—Lovastatin—atherosclerosis	0.00252	0.00335	CcSEcCtD
Travoprost—Cardiac disorder—Pravastatin—atherosclerosis	0.00252	0.00335	CcSEcCtD
Travoprost—Vertigo—Lovastatin—atherosclerosis	0.00252	0.00334	CcSEcCtD
Travoprost—Angiopathy—Niacin—atherosclerosis	0.00251	0.00332	CcSEcCtD
Travoprost—Malaise—Ezetimibe—atherosclerosis	0.00248	0.00328	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—atherosclerosis	0.00247	0.0102	CbGpPWpGaD
Travoprost—Vision blurred—Simvastatin—atherosclerosis	0.00247	0.00327	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00246	0.00326	CcSEcCtD
Travoprost—Ill-defined disorder—Simvastatin—atherosclerosis	0.00243	0.00322	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—KNG1—atherosclerosis	0.00243	0.00998	CbGpPWpGaD
Travoprost—Palpitations—Ezetimibe—atherosclerosis	0.00243	0.00322	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.00242	0.00993	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—AGTR1—atherosclerosis	0.00241	0.00992	CbGpPWpGaD
Travoprost—Erythema—Niacin—atherosclerosis	0.0024	0.00319	CcSEcCtD
Travoprost—Cough—Ezetimibe—atherosclerosis	0.0024	0.00318	CcSEcCtD
Travoprost—Arthralgia—Lovastatin—atherosclerosis	0.00238	0.00316	CcSEcCtD
Travoprost—Chest pain—Lovastatin—atherosclerosis	0.00238	0.00316	CcSEcCtD
Travoprost—Myalgia—Lovastatin—atherosclerosis	0.00238	0.00316	CcSEcCtD
Travoprost—Anxiety—Lovastatin—atherosclerosis	0.00238	0.00315	CcSEcCtD
Travoprost—Dyspepsia—Rosuvastatin—atherosclerosis	0.00237	0.00315	CcSEcCtD
Travoprost—Hypertension—Ezetimibe—atherosclerosis	0.00237	0.00314	CcSEcCtD
Travoprost—Malaise—Simvastatin—atherosclerosis	0.00236	0.00313	CcSEcCtD
Travoprost—Discomfort—Lovastatin—atherosclerosis	0.00236	0.00312	CcSEcCtD
Travoprost—Vertigo—Simvastatin—atherosclerosis	0.00235	0.00312	CcSEcCtD
Travoprost—Tafluprost—PTGS2—atherosclerosis	0.00235	1	CrCbGaD
Travoprost—Chest pain—Ezetimibe—atherosclerosis	0.00234	0.0031	CcSEcCtD
Travoprost—Arthralgia—Ezetimibe—atherosclerosis	0.00234	0.0031	CcSEcCtD
Travoprost—Myalgia—Ezetimibe—atherosclerosis	0.00234	0.0031	CcSEcCtD
Travoprost—Dry mouth—Lovastatin—atherosclerosis	0.00233	0.00309	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00232	0.00308	CcSEcCtD
Travoprost—Dysgeusia—Pravastatin—atherosclerosis	0.00232	0.00307	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CCL4—atherosclerosis	0.00232	0.00952	CbGpPWpGaD
Travoprost—Discomfort—Ezetimibe—atherosclerosis	0.00231	0.00306	CcSEcCtD
Travoprost—Constipation—Rosuvastatin—atherosclerosis	0.00231	0.00306	CcSEcCtD
Travoprost—Pain—Rosuvastatin—atherosclerosis	0.00231	0.00306	CcSEcCtD
Travoprost—Dry mouth—Ezetimibe—atherosclerosis	0.00229	0.00303	CcSEcCtD
Travoprost—Infection—Lovastatin—atherosclerosis	0.00227	0.00301	CcSEcCtD
Travoprost—Vision blurred—Niacin—atherosclerosis	0.00227	0.003	CcSEcCtD
Travoprost—Vision blurred—Pravastatin—atherosclerosis	0.00223	0.00296	CcSEcCtD
Travoprost—Chest pain—Simvastatin—atherosclerosis	0.00223	0.00296	CcSEcCtD
Travoprost—Myalgia—Simvastatin—atherosclerosis	0.00223	0.00296	CcSEcCtD
Travoprost—Arthralgia—Simvastatin—atherosclerosis	0.00223	0.00296	CcSEcCtD
Travoprost—Infection—Ezetimibe—atherosclerosis	0.00223	0.00295	CcSEcCtD
Travoprost—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00222	0.00295	CcSEcCtD
Travoprost—Anxiety—Simvastatin—atherosclerosis	0.00222	0.00295	CcSEcCtD
Travoprost—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.0022	0.00292	CcSEcCtD
Travoprost—Discomfort—Simvastatin—atherosclerosis	0.0022	0.00292	CcSEcCtD
Travoprost—Nervous system disorder—Ezetimibe—atherosclerosis	0.0022	0.00291	CcSEcCtD
Travoprost—Ill-defined disorder—Pravastatin—atherosclerosis	0.0022	0.00291	CcSEcCtD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCR2—atherosclerosis	0.00219	0.00902	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—EDNRA—atherosclerosis	0.00219	0.00902	CbGpPWpGaD
Travoprost—Skin disorder—Ezetimibe—atherosclerosis	0.00218	0.00289	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—atherosclerosis	0.00217	0.00892	CbGpPWpGaD
Travoprost—Vertigo—Niacin—atherosclerosis	0.00216	0.00286	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—atherosclerosis	0.00216	0.00887	CbGpPWpGaD
Travoprost—Oedema—Simvastatin—atherosclerosis	0.00214	0.00283	CcSEcCtD
Travoprost—Malaise—Pravastatin—atherosclerosis	0.00214	0.00283	CcSEcCtD
Travoprost—Abdominal pain—Rosuvastatin—atherosclerosis	0.00213	0.00283	CcSEcCtD
Travoprost—Vertigo—Pravastatin—atherosclerosis	0.00213	0.00282	CcSEcCtD
Travoprost—Palpitations—Niacin—atherosclerosis	0.00213	0.00282	CcSEcCtD
Travoprost—Infection—Simvastatin—atherosclerosis	0.00212	0.00282	CcSEcCtD
Travoprost—Cough—Niacin—atherosclerosis	0.0021	0.00278	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00208	0.00276	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.00208	0.00854	CbGpPWpGaD
Travoprost—Cough—Pravastatin—atherosclerosis	0.00207	0.00274	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—UTS2—atherosclerosis	0.00207	0.00849	CbGpPWpGaD
Travoprost—Myalgia—Niacin—atherosclerosis	0.00205	0.00271	CcSEcCtD
Travoprost—Arthralgia—Niacin—atherosclerosis	0.00205	0.00271	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—EDN1—atherosclerosis	0.00205	0.00841	CbGpPWpGaD
Travoprost—Hypertension—Pravastatin—atherosclerosis	0.00204	0.00271	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00204	0.00271	CcSEcCtD
Travoprost—Dyspnoea—Lovastatin—atherosclerosis	0.00204	0.0027	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00203	0.0027	CcSEcCtD
Travoprost—Myalgia—Pravastatin—atherosclerosis	0.00202	0.00267	CcSEcCtD
Travoprost—Chest pain—Pravastatin—atherosclerosis	0.00202	0.00267	CcSEcCtD
Travoprost—Arthralgia—Pravastatin—atherosclerosis	0.00202	0.00267	CcSEcCtD
Travoprost—Dyspepsia—Lovastatin—atherosclerosis	0.00201	0.00267	CcSEcCtD
Travoprost—Anxiety—Pravastatin—atherosclerosis	0.00201	0.00266	CcSEcCtD
Travoprost—Dry mouth—Niacin—atherosclerosis	0.002	0.00265	CcSEcCtD
Travoprost—Dyspnoea—Ezetimibe—atherosclerosis	0.002	0.00265	CcSEcCtD
Travoprost—Discomfort—Pravastatin—atherosclerosis	0.00199	0.00264	CcSEcCtD
Travoprost—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00199	0.00263	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CX3CR1—atherosclerosis	0.00198	0.00814	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CASR—atherosclerosis	0.00198	0.00814	CbGpPWpGaD
Travoprost—Dyspepsia—Ezetimibe—atherosclerosis	0.00197	0.00262	CcSEcCtD
Travoprost—Fatigue—Lovastatin—atherosclerosis	0.00197	0.00261	CcSEcCtD
Travoprost—Oedema—Niacin—atherosclerosis	0.00196	0.0026	CcSEcCtD
Travoprost—Pain—Lovastatin—atherosclerosis	0.00195	0.00259	CcSEcCtD
Travoprost—Constipation—Lovastatin—atherosclerosis	0.00195	0.00259	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00195	0.00258	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CX3CL1—atherosclerosis	0.00194	0.00798	CbGpPWpGaD
Travoprost—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00193	0.00257	CcSEcCtD
Travoprost—Asthenia—Rosuvastatin—atherosclerosis	0.00193	0.00256	CcSEcCtD
Travoprost—Oedema—Pravastatin—atherosclerosis	0.00193	0.00256	CcSEcCtD
Travoprost—Fatigue—Ezetimibe—atherosclerosis	0.00193	0.00256	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—atherosclerosis	0.00192	0.00791	CbGpPWpGaD
Travoprost—Infection—Pravastatin—atherosclerosis	0.00192	0.00255	CcSEcCtD
Travoprost—Pain—Ezetimibe—atherosclerosis	0.00192	0.00254	CcSEcCtD
Travoprost—Constipation—Ezetimibe—atherosclerosis	0.00192	0.00254	CcSEcCtD
Travoprost—Tachycardia—Niacin—atherosclerosis	0.00192	0.00254	CcSEcCtD
Travoprost—Pruritus—Rosuvastatin—atherosclerosis	0.00191	0.00253	CcSEcCtD
Travoprost—Skin disorder—Niacin—atherosclerosis	0.00191	0.00253	CcSEcCtD
Travoprost—Dyspnoea—Simvastatin—atherosclerosis	0.00191	0.00253	CcSEcCtD
Travoprost—Feeling abnormal—Lovastatin—atherosclerosis	0.00188	0.0025	CcSEcCtD
Travoprost—Dyspepsia—Simvastatin—atherosclerosis	0.00188	0.00249	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.00188	0.00772	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.00188	0.00772	CbGpPWpGaD
Travoprost—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00187	0.00248	CcSEcCtD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	0.00187	0.00767	CbGpPWpGaD
Travoprost—Feeling abnormal—Ezetimibe—atherosclerosis	0.00185	0.00245	CcSEcCtD
Travoprost—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00185	0.00245	CcSEcCtD
Travoprost—Diarrhoea—Rosuvastatin—atherosclerosis	0.00184	0.00245	CcSEcCtD
Travoprost—Fatigue—Simvastatin—atherosclerosis	0.00184	0.00244	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CNR2—atherosclerosis	0.00184	0.00756	CbGpPWpGaD
Travoprost—Hypotension—Niacin—atherosclerosis	0.00183	0.00243	CcSEcCtD
Travoprost—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00183	0.00243	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.00183	0.00753	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—atherosclerosis	0.00183	0.00752	CbGpPWpGaD
Travoprost—Pain—Simvastatin—atherosclerosis	0.00183	0.00242	CcSEcCtD
Travoprost—Constipation—Simvastatin—atherosclerosis	0.00183	0.00242	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—HRH1—atherosclerosis	0.00181	0.00744	CbGpPWpGaD
Travoprost—Abdominal pain—Lovastatin—atherosclerosis	0.00181	0.00239	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00179	0.00237	CcSEcCtD
Travoprost—Dizziness—Rosuvastatin—atherosclerosis	0.00178	0.00236	CcSEcCtD
Travoprost—Abdominal pain—Ezetimibe—atherosclerosis	0.00177	0.00235	CcSEcCtD
Travoprost—Feeling abnormal—Simvastatin—atherosclerosis	0.00176	0.00234	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00176	0.00233	CcSEcCtD
Travoprost—Dyspnoea—Niacin—atherosclerosis	0.00175	0.00232	CcSEcCtD
Travoprost—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00175	0.00232	CcSEcCtD
Travoprost—Dyspepsia—Niacin—atherosclerosis	0.00173	0.00229	CcSEcCtD
Travoprost—Dyspnoea—Pravastatin—atherosclerosis	0.00172	0.00228	CcSEcCtD
Travoprost—Dyspepsia—Pravastatin—atherosclerosis	0.0017	0.00226	CcSEcCtD
Travoprost—Rash—Rosuvastatin—atherosclerosis	0.0017	0.00225	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—AGT—atherosclerosis	0.0017	0.00698	CbGpPWpGaD
Travoprost—Dermatitis—Rosuvastatin—atherosclerosis	0.0017	0.00225	CcSEcCtD
Travoprost—Gastrointestinal disorder—Niacin—atherosclerosis	0.00169	0.00225	CcSEcCtD
Travoprost—Abdominal pain—Simvastatin—atherosclerosis	0.00169	0.00224	CcSEcCtD
Travoprost—Headache—Rosuvastatin—atherosclerosis	0.00169	0.00224	CcSEcCtD
Travoprost—Hypersensitivity—Lovastatin—atherosclerosis	0.00168	0.00223	CcSEcCtD
Travoprost—Pain—Niacin—atherosclerosis	0.00168	0.00223	CcSEcCtD
Travoprost—Fatigue—Pravastatin—atherosclerosis	0.00167	0.00221	CcSEcCtD
Travoprost—Constipation—Pravastatin—atherosclerosis	0.00165	0.00219	CcSEcCtD
Travoprost—Pain—Pravastatin—atherosclerosis	0.00165	0.00219	CcSEcCtD
Travoprost—Hypersensitivity—Ezetimibe—atherosclerosis	0.00165	0.00219	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—HRH1—atherosclerosis	0.00164	0.00676	CbGpPWpGaD
Travoprost—Asthenia—Lovastatin—atherosclerosis	0.00164	0.00217	CcSEcCtD
Travoprost—Pruritus—Lovastatin—atherosclerosis	0.00162	0.00214	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.00161	0.00661	CbGpPWpGaD
Travoprost—Asthenia—Ezetimibe—atherosclerosis	0.00161	0.00213	CcSEcCtD
Travoprost—Gastrointestinal pain—Niacin—atherosclerosis	0.0016	0.00213	CcSEcCtD
Travoprost—Nausea—Rosuvastatin—atherosclerosis	0.0016	0.00212	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.0016	0.00657	CbGpPWpGaD
Travoprost—Feeling abnormal—Pravastatin—atherosclerosis	0.00159	0.00211	CcSEcCtD
Travoprost—Pruritus—Ezetimibe—atherosclerosis	0.00159	0.0021	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CCL3—atherosclerosis	0.00158	0.0065	CbGpPWpGaD
Travoprost—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00158	0.00209	CcSEcCtD
Travoprost—Hypersensitivity—Simvastatin—atherosclerosis	0.00157	0.00209	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—F2—atherosclerosis	0.00157	0.00645	CbGpPWpGaD
Travoprost—Diarrhoea—Lovastatin—atherosclerosis	0.00156	0.00207	CcSEcCtD
Travoprost—Abdominal pain—Niacin—atherosclerosis	0.00155	0.00206	CcSEcCtD
Travoprost—Asthenia—Simvastatin—atherosclerosis	0.00153	0.00203	CcSEcCtD
Travoprost—Diarrhoea—Ezetimibe—atherosclerosis	0.00153	0.00203	CcSEcCtD
Travoprost—Abdominal pain—Pravastatin—atherosclerosis	0.00153	0.00203	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	0.00152	0.00624	CbGpPWpGaD
Travoprost—Pruritus—Simvastatin—atherosclerosis	0.00151	0.002	CcSEcCtD
Travoprost—Dizziness—Lovastatin—atherosclerosis	0.00151	0.002	CcSEcCtD
Travoprost—Dizziness—Ezetimibe—atherosclerosis	0.00148	0.00196	CcSEcCtD
Travoprost—Diarrhoea—Simvastatin—atherosclerosis	0.00146	0.00194	CcSEcCtD
Travoprost—Hypersensitivity—Niacin—atherosclerosis	0.00145	0.00192	CcSEcCtD
Travoprost—Rash—Lovastatin—atherosclerosis	0.00144	0.00191	CcSEcCtD
Travoprost—Dermatitis—Lovastatin—atherosclerosis	0.00144	0.00191	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CCR2—atherosclerosis	0.00143	0.00588	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—EDNRA—atherosclerosis	0.00143	0.00588	CbGpPWpGaD
Travoprost—Headache—Lovastatin—atherosclerosis	0.00143	0.0019	CcSEcCtD
Travoprost—Hypersensitivity—Pravastatin—atherosclerosis	0.00142	0.00189	CcSEcCtD
Travoprost—Dizziness—Simvastatin—atherosclerosis	0.00141	0.00187	CcSEcCtD
Travoprost—Rash—Ezetimibe—atherosclerosis	0.00141	0.00187	CcSEcCtD
Travoprost—Dermatitis—Ezetimibe—atherosclerosis	0.00141	0.00187	CcSEcCtD
Travoprost—Asthenia—Niacin—atherosclerosis	0.00141	0.00187	CcSEcCtD
Travoprost—Headache—Ezetimibe—atherosclerosis	0.0014	0.00186	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	0.0014	0.00577	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—GHRL—atherosclerosis	0.0014	0.00573	CbGpPWpGaD
Travoprost—Pruritus—Niacin—atherosclerosis	0.00139	0.00184	CcSEcCtD
Travoprost—Asthenia—Pravastatin—atherosclerosis	0.00139	0.00184	CcSEcCtD
Travoprost—Pruritus—Pravastatin—atherosclerosis	0.00137	0.00181	CcSEcCtD
Travoprost—Nausea—Lovastatin—atherosclerosis	0.00136	0.0018	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.00136	0.00557	CbGpPWpGaD
Travoprost—Rash—Simvastatin—atherosclerosis	0.00135	0.00179	CcSEcCtD
Travoprost—Dermatitis—Simvastatin—atherosclerosis	0.00135	0.00179	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.00134	0.00552	CbGpPWpGaD
Travoprost—Diarrhoea—Niacin—atherosclerosis	0.00134	0.00178	CcSEcCtD
Travoprost—Headache—Simvastatin—atherosclerosis	0.00134	0.00178	CcSEcCtD
Travoprost—Nausea—Ezetimibe—atherosclerosis	0.00133	0.00176	CcSEcCtD
Travoprost—Diarrhoea—Pravastatin—atherosclerosis	0.00132	0.00175	CcSEcCtD
Travoprost—Dizziness—Niacin—atherosclerosis	0.0013	0.00172	CcSEcCtD
Travoprost—Dizziness—Pravastatin—atherosclerosis	0.00128	0.00169	CcSEcCtD
Travoprost—Nausea—Simvastatin—atherosclerosis	0.00127	0.00168	CcSEcCtD
Travoprost—Rash—Niacin—atherosclerosis	0.00124	0.00164	CcSEcCtD
Travoprost—Dermatitis—Niacin—atherosclerosis	0.00124	0.00164	CcSEcCtD
Travoprost—Headache—Niacin—atherosclerosis	0.00123	0.00163	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—KNG1—atherosclerosis	0.00122	0.00503	CbGpPWpGaD
Travoprost—Rash—Pravastatin—atherosclerosis	0.00122	0.00162	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—AGTR1—atherosclerosis	0.00122	0.005	CbGpPWpGaD
Travoprost—Dermatitis—Pravastatin—atherosclerosis	0.00122	0.00161	CcSEcCtD
Travoprost—Headache—Pravastatin—atherosclerosis	0.00121	0.0016	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—CCL4—atherosclerosis	0.00119	0.00489	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—UTS2—atherosclerosis	0.00117	0.0048	CbGpPWpGaD
Travoprost—Nausea—Niacin—atherosclerosis	0.00117	0.00155	CcSEcCtD
Travoprost—Nausea—Pravastatin—atherosclerosis	0.00115	0.00152	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.00112	0.00462	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CASR—atherosclerosis	0.00112	0.0046	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—UTS2—atherosclerosis	0.00106	0.00435	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CNR2—atherosclerosis	0.00104	0.00427	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.00104	0.00427	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—EDN1—atherosclerosis	0.00103	0.00424	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CCL5—atherosclerosis	0.00102	0.00421	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CX3CR1—atherosclerosis	0.00102	0.00418	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CASR—atherosclerosis	0.00102	0.00418	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CX3CL1—atherosclerosis	0.000997	0.00409	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HRH1—atherosclerosis	0.000972	0.00399	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CNR2—atherosclerosis	0.000945	0.00388	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000926	0.00381	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—AGT—atherosclerosis	0.000857	0.00352	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCL3—atherosclerosis	0.000812	0.00334	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—EDNRA—atherosclerosis	0.000809	0.00332	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CCR2—atherosclerosis	0.000809	0.00332	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—F2—atherosclerosis	0.000792	0.00325	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GHRL—atherosclerosis	0.000788	0.00324	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APOA4—atherosclerosis	0.000762	0.00313	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	0.00076	0.00312	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—EDNRA—atherosclerosis	0.000735	0.00302	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCR2—atherosclerosis	0.000735	0.00302	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000732	0.00301	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GHRL—atherosclerosis	0.000716	0.00294	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CCL2—atherosclerosis	0.000705	0.0029	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCL4—atherosclerosis	0.000703	0.00289	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—KNG1—atherosclerosis	0.000692	0.00284	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AGTR1—atherosclerosis	0.000688	0.00283	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APOA2—atherosclerosis	0.000656	0.0027	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—KNG1—atherosclerosis	0.000628	0.00258	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—UTS2—atherosclerosis	0.000626	0.00257	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AGTR1—atherosclerosis	0.000625	0.00257	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CX3CR1—atherosclerosis	0.0006	0.00247	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CASR—atherosclerosis	0.0006	0.00247	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CX3CL1—atherosclerosis	0.000589	0.00242	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—EDN1—atherosclerosis	0.000583	0.0024	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CCL5—atherosclerosis	0.000579	0.00238	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CNR2—atherosclerosis	0.000558	0.00229	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCL8—atherosclerosis	0.000558	0.00229	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MMP3—atherosclerosis	0.000557	0.00229	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	0.000556	0.00228	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PRKCG—atherosclerosis	0.00055	0.00226	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—EDN1—atherosclerosis	0.00053	0.00218	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCL5—atherosclerosis	0.000526	0.00216	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PRKCG—atherosclerosis	0.0005	0.00205	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VWF—atherosclerosis	0.000497	0.00204	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APOC3—atherosclerosis	0.000494	0.00203	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LDLR—atherosclerosis	0.000491	0.00202	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AGT—atherosclerosis	0.000484	0.00199	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCL3—atherosclerosis	0.00048	0.00197	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NCF1—atherosclerosis	0.00046	0.00189	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—F2—atherosclerosis	0.000447	0.00184	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AGT—atherosclerosis	0.00044	0.00181	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCR2—atherosclerosis	0.000434	0.00178	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EDNRA—atherosclerosis	0.000434	0.00178	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CYBA—atherosclerosis	0.000432	0.00178	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000428	0.00176	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PLAT—atherosclerosis	0.000423	0.00174	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PARP1—atherosclerosis	0.000423	0.00174	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GHRL—atherosclerosis	0.000423	0.00174	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—F2—atherosclerosis	0.000406	0.00167	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CG—atherosclerosis	0.000389	0.0016	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KNG1—atherosclerosis	0.000371	0.00153	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AGTR1—atherosclerosis	0.000369	0.00152	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCL2—atherosclerosis	0.000362	0.00149	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PLG—atherosclerosis	0.00036	0.00148	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SOCS3—atherosclerosis	0.000341	0.0014	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MMP3—atherosclerosis	0.000329	0.00135	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IGF2—atherosclerosis	0.000327	0.00135	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APOB—atherosclerosis	0.000318	0.00131	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCL8—atherosclerosis	0.000315	0.00129	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EDN1—atherosclerosis	0.000313	0.00129	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCL5—atherosclerosis	0.00031	0.00128	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LPL—atherosclerosis	0.000304	0.00125	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PRKCG—atherosclerosis	0.000295	0.00121	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SPP1—atherosclerosis	0.000287	0.00118	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCL8—atherosclerosis	0.000286	0.00118	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDGFB—atherosclerosis	0.000266	0.00109	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AGT—atherosclerosis	0.00026	0.00107	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LEP—atherosclerosis	0.000254	0.00105	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APOE—atherosclerosis	0.000254	0.00105	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CAV1—atherosclerosis	0.000252	0.00104	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APOA1—atherosclerosis	0.000252	0.00103	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ESR1—atherosclerosis	0.000243	0.000998	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—F2—atherosclerosis	0.00024	0.000986	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CG—atherosclerosis	0.00023	0.000943	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MAPK3—atherosclerosis	0.00022	0.000904	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—INS—atherosclerosis	0.000217	0.000893	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCL2—atherosclerosis	0.000214	0.000879	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IGF1—atherosclerosis	0.00021	0.000864	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SERPINE1—atherosclerosis	0.0002	0.00082	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NOS3—atherosclerosis	0.000191	0.000783	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCL8—atherosclerosis	0.000169	0.000695	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AKT1—atherosclerosis	0.000163	0.000671	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL6—atherosclerosis	0.000161	0.000661	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MMP9—atherosclerosis	0.000153	0.000628	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NFKB1—atherosclerosis	0.000151	0.000622	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAPK8—atherosclerosis	0.000149	0.000611	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AKT1—atherosclerosis	0.000148	0.000609	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VEGFA—atherosclerosis	0.000137	0.000564	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STAT3—atherosclerosis	0.000136	0.000559	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAPK3—atherosclerosis	0.00013	0.000534	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TGFB1—atherosclerosis	0.000126	0.000518	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL6—atherosclerosis	9.5e-05	0.00039	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AKT1—atherosclerosis	8.76e-05	0.00036	CbGpPWpGaD
